Loading…

Loading grant details…

Completed HORIZON European Commission

Radical Improvement of Cancer Treatment without Additional Negative Side Effects

€8.57M EUR

Funder European Commission
Recipient Organization Sensius Bv
Country Netherlands
Start Date Jan 01, 2022
End Date Jun 30, 2025
Duration 1,276 days
Number of Grantees 1
Roles Coordinator
Data Source European Commission
Grant ID 190101940
Grant Description

We have developed a device – called HyperCollar4D – that significantly increases the effectiveness of radiotherapy for head and neck (H&N) cancer.

The first results on 70 patients have proven that our technology yields +50% complete response with respect to radiotherapy alone. The HyperCollar4D is based on hyperthermia: warming up the tumor to 43 ˚C improves its sensitivity to radiotherapy. Hyperthermia yields no lasting toxicity, unlike radiotherapy and chemotherapy.

The challenge with hyperthermia is delivering it effectively (i.e., heating only the tumor and not the nearby tissues) and cost-efficiently. The HyperCollar4D is the first device to achieve effective and cost-efficient hyperthermia treatments for H&N cancer. Our technology (called ‘thermotherapy’) is protected by two patents (one granted and one filed).

The HyperCollar4D design is modular, so it can be extended to add modules to treat other kinds of cancers. Sensius is a spin-off of the Erasmus Medical Center.

All Grantees

Sensius Bv

Advertisement
Discover thousands of grant opportunities
Advertisement
Browse Grants on GrantFunds
Interested in applying for this grant?

Complete our application form to express your interest and we'll guide you through the process.

Apply for This Grant